The Royal Marsden (Surrey) | Oak Foundation Drug Development Unit
The Royal Marsden (Surrey) | Oak Foundation Drug Development Unit
Sutton, Surrey, United Kingdom2 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) | Metastatic Castration-resistant Prostate Cancer | Active, not recruiting | Phase 1 | 2026-09-24 | NCT06052306 | |
| A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation | Advanced Solid Tumors Harboring KRAS G12C Mutation | Recruiting | Phase 1 | 2026-09-23 | NCT06659341 |